These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22203732)

  • 21. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
    Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
    Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
    J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.
    Bröker LE; de Vos FY; van Groeningen CJ; Kuenen BC; Gall HE; Woo MH; Voi M; Gietema JA; de Vries EG; Giaccone G
    Clin Cancer Res; 2006 Mar; 12(6):1760-7. PubMed ID: 16551860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study.
    Horton TM; Ames MM; Reid JM; Krailo MD; Pendergrass T; Mosher R; Reaman GH; Seibel NL;
    Pediatr Blood Cancer; 2008 Apr; 50(4):788-92. PubMed ID: 17668866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
    Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors.
    Mukai H; Kato K; Esaki T; Ohsumi S; Hozomi Y; Matsubara N; Hamaguchi T; Matsumura Y; Goda R; Hirai T; Nambu Y
    Invest New Drugs; 2016 Dec; 34(6):750-759. PubMed ID: 27595901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.
    Sessa C; Cuvier C; Caldiera S; Bauer J; Van Den Bosch S; Monnerat C; Semiond D; Pérard D; Lebecq A; Besenval M; Marty M
    Ann Oncol; 2002 Jul; 13(7):1140-50. PubMed ID: 12176795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.
    Gelmon KA; Latreille J; Tolcher A; Génier L; Fisher B; Forand D; D'Aloisio S; Vernillet L; Daigneault L; Lebecq A; Besenval M; Eisenhauer E
    J Clin Oncol; 2000 Dec; 18(24):4098-108. PubMed ID: 11118471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
    Hong YS; Kim KP; Lim HS; Bae KS; Ryu MH; Lee JL; Chang HM; Kang YK; Kim H; Kim TW
    Invest New Drugs; 2013 Jun; 31(3):616-22. PubMed ID: 22695940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
    Kouroussis C; Kakolyris S; Mavroudis D; Androulakis N; Kalbakis K; Agelaki S; Sarra E; Souglakos J; Christodoulakis M; Samonis G; Georgoulias V
    Am J Clin Oncol; 2001 Aug; 24(4):404-7. PubMed ID: 11474274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
    Hidalgo M; Aylesworth C; Hammond LA; Britten CD; Weiss G; Stephenson J; Schwartz G; Patnaik A; Smith L; Molpus K; Felton S; Gupta E; Ferrante KJ; Tortora A; Sonnichsen DS; Skillings J; Rowinsky EK
    J Clin Oncol; 2001 May; 19(9):2493-503. PubMed ID: 11331328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
    Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
    Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
    J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
    Soepenberg O; Sparreboom A; de Jonge MJ; Planting AS; de Heus G; Loos WJ; Hartman CM; Bowden C; Verweij J
    Eur J Cancer; 2004 Mar; 40(5):681-8. PubMed ID: 15010068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
    Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
    J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
    Braybrooke JP; Boven E; Bates NP; Ruijter R; Dobbs N; Cheverton PD; Pinedo HM; Talbot DC
    Ann Oncol; 2003 Jun; 14(6):913-21. PubMed ID: 12796030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
    Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
    Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.